A beta-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients

作者：Komatsu Nobukazu^*; Terasaki Yasunobu; Moriya Fukuko; Suekane Shigetaka; Noguchi Masanori; Todo Satoru; Itoh Kyogo; Shichijo Shigeki

来源：Experimental and Therapeutic Medicine, 2010, 1(5): 833-839.

DOI：10.3892/etm.2010.120

• beta-tubulin 5
• peptide
• cytotoxic T lymphocyte
• HLA-A24
• cancer vaccine
• peripheral blood mononuclear cell
• prostate cancer

To facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce H LA-class I-restricted cytotoxic T lymphocyte (CTL) activity in HLA-A3 supertype (-A3, -A11, -A31 and -A33)-positive prostate cancer patients are also capable of inducing CTLs restricted to HLA-A2, HLA-A24 or HLA-A26 alleles. Among the 13 peptides tested, a peptide at positions 309 to 318 of beta-tubulin 5 exhibited binding activity to the HLA-A*2402 molecule and induced HLA-A24-restricted CTL activity against prostate cancer cells derived from peripheral blood mononuclear cells of prostate cancer patients. The CTL activity was determined to be specific to this peptide and was mediated by CD8(+) T cells in an H:LA-class I-restricted manner. These results suggest that this peptide could be applicable as a peptide vaccine, not only for HLA-A3 supertype-positive, but also for HLA-A24-positive prostate cancer patients.

• 出版日期2010-10